A Phase I, Safety, Tolerability, and Pharmacokinetic Interaction Study of Single-Dose TMC207 and Efavirenz in Healthy Volunteers.

Trial Profile

A Phase I, Safety, Tolerability, and Pharmacokinetic Interaction Study of Single-Dose TMC207 and Efavirenz in Healthy Volunteers.

Completed
Phase of Trial: Phase I

Latest Information Update: 03 Apr 2013

At a glance

  • Drugs Bedaquiline (Primary) ; Efavirenz
  • Indications HIV infections; Tuberculosis
  • Focus Adverse reactions; Pharmacokinetics
  • Most Recent Events

    • 27 Apr 2012 Actual end date changed from Jul 2011 to Dec 2010 as reported by ClinicalTrials.gov.
    • 24 Feb 2012 Actual patient number is 37 according to ClinicalTrials.gov.
    • 24 Feb 2012 Actual end date changed from Dec 2010 to 1 Jul 2011 as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top